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Abstract
Background: There have been a limited number of studies comparing bone mass between patients with
schizophrenia and the general population. The aim of this study was to compare the bone mass of schizophrenia
patients with that of healthy subjects in Japan.
Methods: We recruited patients (n = 362), aged 48.8 ± 15.4 (mean ± SD) years who were diagnosed with
schizophrenia or schizoaffective disorder based on the Diagnostic and Statistical Manual of Mental Disorders, fourth
edition (DSM-IV). Bone mass was measured using quantitative ultrasound densitometry of the calcaneus. The
osteosono-assessment index (OSI) was calculated as a function of the speed of sound and the transmission index.
For comparative analysis, OSI data from 832 adults who participated in the Iwaki Health Promotion Project 2009
was used as representative of the general community.
Results: Mean OSI values among male schizophrenic patients were lower than those in the general population in
the case of individuals aged 40 and older. In females, mean OSI values among schizophrenic patients were lower
than those in the general community in those aged 60 and older. In an analysis using the general linear model, a
significant interaction was observed between subject groups and age in males.
Conclusions: Older schizophrenic patients exhibit lower bone mass than that observed in the general population.
Our data also demonstrate gender and group differences among schizophrenic patients and controls with regard
to changes in bone mass associated with aging. These results indicate that intervention programs designed to
delay or prevent decreased bone mass in schizophrenic patients might be tailored according to gender.
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Introduction
It has previously been shown that patients taking anti-
psychotic medications are at greater risk for bone frac-
tures [1]. The onset of schizophrenia typically occurs
during adolescence and young adulthood [2], therefore,
the administration of antipsychotic medications gener-
ally begins during the same period, during which bone
maturation results in peak bone mass.
In previous studies that have considered decreased
bone mass in patients with schizophrenia, factors asso-
ciated with accelerated bone absorption have included
polydipsia [3], use of neuroleptics [4] and the resulting
hyperprolactinemia [5,6], heavy smoking [7], poor diet,
drug and alcohol abuse [8], and lack of exercise [9].
However, to date there have been a limited number of
studies [10-12] comparing bone mass between patients
with schizophrenia and the general population. It is
therefore necessary to accurately examine the nature of
bone mass deficiencies in schizophrenic patients in a
cross-sectional manner with an age-matched healthy
control group for comparison.
In recent years, a quantitative ultrasound (QUS) densi-
tometry technique has been developed for measuring
bone mass. The results obtained using QUS are reported
to correlate well with those using dual energy x-ray
absorptiometry (DXA) [13]. Furthermore, QUS can pro-
vide data on the risk for osteoporosis related fractures
[14,15]. QUS is a relatively quick procedure that is
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making it suitable for research projects examining large
numbers of subjects [16].
T h ea i mo ft h i ss t u d yw a st oc o m p a r eb o n em a s s
between patients with schizophrenia and healthy indivi-
duals using QUS. To the best of our knowledge, this is
t h el a r g e s ts t u d yo ft h i sn a t u r et ob ec a r r i e do u ti n
Japan.
Methods
Participants
The subject pool consisted of 362 patients (178 males
and 184 females) who were diagnosed with either schi-
zophrenia or schizoaffective disorder based on Diagnos-
tic and Statistical Manual of Mental Disorders,f o u r t h
edition (DSM-IV) criteria at 3 psychiatric hospitals in
J a p a n .T h ed i a g n o s e so ft h ep a t i e n t sw e r ed e t e r m i n e d
based on medical records. As a reference group, 832
healthy volunteers (327 males and 505 females) who
participated in the Iwaki Health Promotion Project in
2009 were also included. They were residents of Iwaki
district, Hirosaki city, in northern Japan. Iwaki district is
a stable community with a population 11, 961. Their
demographic data (age and sex) and medical history
were obtained from self-report questionnaires and inter-
views. Data obtained from the meteorological agency
website showed that environmental conditions (duration
of sunshine, length of day, temperature and humidity)
were similar in the three hospitals and control survey
[17]. The data collection procedures for this study were
approved (no. 2008-122) by the Ethics Committee of the
Hirosaki University School of Medicine and all subjects
provided written informed consent before participating.
Procedure
Subject demographic data (age and sex) was obtained
from their medical records. Bone mass was evaluated via
QUS densitometry using the AOS-100 device (Aloka,
Co. Ltd., Tokyo, Japan) at the calcaneus. The AOS-100
evaluates the speed of sound (SOS in m/s) and the
transmission index (TI). SOS and TI as measured using
the AOS-100, are highly correlated with SOS (r = 0.89)
and broadband ultrasound attenuation (BUA) (r = 0.88)
measures obtained using a conventional QUS device
[18]. The osteosono-assessment index (OSI) was calcu-
lated as a function of SOS and TI, using the TI value
multiplied by the square of the SOS value [19]. We
assessed the precision of quantitative ultrasound densi-
tometry, and intratest precis i o nw a sc a l c u l a t e df r o m3
repeated scans with repositioning in 17 volunteers; the
short-term coefficient of variation was 2.6% for the OSI
measure [20]. Low bone mass was defined as a level
equal to or less than -1.0 standard deviation below the
mean OSI value of the reference group aged 20 to 39
years old. Severe low bone mass was defined as a level
equal to or less than -2.5 standard deviations below the
mean OSI value of the reference group.
Statistical analysis
Subjects were classified into two groups, with recruited
schizophrenic patients composing the schizophrenic
patient group and community residents composing the
general population group. To compare the main demo-
graphic and clinical characteristics between schizo-
phrenic patients and the community group, an
unpaired Student’s t test was performed to analyze
continuous variables, and a c
2 test or Fisher’s exact
test was used for categorical variables. Data are pre-
sented as mean ± SD. Subjects were classified into six
age groups, with those aged 20 to 69 grouped accord-
ing to decade and one group for those 70 and older. In
addition, subjects were classified into two larger groups
(the younger group with those aged 20 to 49, and the
older group for those aged 50 and older) to analyze
the effect of aging. The relationship between OSI
values and age was tested using simple linear regres-
sion analysis. To determine the factors associated with
the measured OSI value, a general linear model analy-
sis that included age and subject groups was employed.
Interactions between age and subject group were also
tested in the same model. A value of P < 0.05 was con-
sidered significant. The data were analyzed using
PASW Statistics software for Windows, V. 18.0.0
(SPSS Inc., Chicago, IL, USA).
Results
Demographic characteristics
The demographic data and OSI values separated by sub-
ject group, age groups and gender are presented in
Table 1. The mean age was 48.0 ± 14.9 years in the
male patients and 49.7 ± 15.9 years in female patients.
In the general population group, the mean age was 56.0
± 13.8 years in males and 58.1 ± 13.0 years in females.
Mean OSI values were lower in male schizophrenic
patients compared with males in the community group
in individuals 40 and older. In females, mean OSI values
were also lower for schizophrenic patients compared
with the community group in those 60 and older.
Intragroup analysis as comparisons between younger
and older group has shown significantly lower OSI
values of the older group in both male schizophrenic
patients (P < 0.001) and community group (P < 0.01).
Among females, the older group also showed signifi-
cantly lower OSI values than the younger group in both
schizophrenic patients (P < 0.001) and community
group (P < 0.001).
Trends in OSI values are depicted in Figure 1. A sig-
nificant relationship between mean OSI value and age
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P < 0.001) for schizophrenic patients. The trend was
also significant among males (P < 0.01) and females (P
< 0.001) in the general population.
Prevalence of low bone mass
Table 2 shows the prevalence of low bone mass (t score
< -1 computed from OSI value) and severe low bone
mass (t score < -2.5 computed from OSI value) in schi-
zophrenic patient group compared to the community
group. In males, the prevalence of low bone mass
among schizophrenic patients is higher than that in the
community group among age groups beginning at 30
years old. Furthermore, the prevalence of severe low
bone mass among schizophrenic patients is higher than
in community group in the 70 and older age group. In
f e m a l e s ,t h ep r e v a l e n c eo fs e v e r el o wb o n em a s sa m o n g
schizophrenic patients is higher than that in the com-
munity group for age groups 60 and older.
Comparison of OSI with age and disease status in each
gender using general linear model
Table 3 shows the general linear model results for the
association between subject group, age, and OSI. In
males, OSI values in schizophrenic patients are signifi-
cantly lower than those in the general population (P <
0.05). A significant effect of age on OSI value is also
observed. Furthermore, a significant interaction can be
observed between subject group and age in males. In
f e m a l e s ,as i g n i f i c a n te f f e c to fa g eo nO S Iv a l u ei s
observed.
Discussion
This study was designed to evaluate the effects of age
and disease on bone mass in patients diagnosed with
schizophrenia. In both males and females, schizophrenic
patients had lower bone mass than that of the general
population in age groups of 60 years and older. A des-
cending trend between mean OSI value and age was
observed in both genders in the schizophrenic patients
and in the community group. However, a significant
interaction between subject group and age in general
linear model showed that descending trend of OSI value
with aging was accelerated in male schizophrenic
patients.
Several previous studies have compared bone mass
between schizophrenic patients and the general popula-
tion. In a large Taiwanese study, Renn et al.[ 1 1 ]
reported that 965 schizophrenic patients had lower bone
mass values than those observed in the general popula-
tion under the age of 50 in both genders. However,
bone mass was higher in schizophrenic patients over the
age of 60 than in the general population in both gen-
ders, indication that an aging effect on bone mass was
not observed in schizophrenic patients. However, Kishi-
moto et al. [10] reported that bone mass among 74
male schizophrenic patients was lower than in the gen-
e r a lp o p u l a t i o ni nt h ea g eg r o u po f4 0t o4 9a n d5 5t o
79. Furthermore, Jung et al. [12] also reported that 229
schizophrenic patients over age 50 had a higher preva-
lence of osteoporosis than healthy controls. In addition
to the comparison studies with the general population,
Liu-Seifert et al. [21] reported that low bone mineral
Table 1 Basic characteristics of schizophrenic patients compared to the general community in Japanese subjects
Age subgroup, years Subjects OSI
Schizophrenia, n Community, n Schizophrenia, mean (SD) Community, mean (SD)
Male:
20 to 29 20 15 3.13 ± 0.35 2.97 ± 0.52
30 to 39 43 28 2.89 ± 0.49 3.06 ± 0.46
40 to 49 32 57 2.76 ± 0.55* 2.96 ± 0.38
50 to 59 40 90 2.68 ± 0.43* 2.86 ± 0.32
60 to 69 30 76 2.57 ± 0.56* 2.87 ± 0.40
70 or older 13 61 2.10 ± 0.37* 2.84 ± 0.51
Total 178 327
Female:
20 to 29 24 15 2.80 ± 0.38 2.88 ± 0.34
30 to 39 32 40 2.98 ± 0.67 2.85 ± 0.37
40 to 49 34 62 2.72 ± 0.36 2.74 ± 0.32
50 to 59 39 136 2.48 ± 0.28 2.55 ± 0.36
60 to 69 28 150 2.20 ± 0.30* 2.37 ± 0.24
70 or older 27 102 2.08 ± 0.22* 2.27 ± 0.23
Total 184 505
Student’s unpaired t test was used to evaluate the differences of osteosono-assessment index (OSI) values between schizophrenic patients and general
community. *P < 0.05.
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both genders among schizophrenic patients.
One possible explanation for the discrepancies
observed regarding aging effects on bone mass among
older schizophrenic patients is that those with the great-
est bone fracture risk may expire at a relatively young
age, leaving a cohort of survivors in the patient group
over 60 years of age in the Taiwanese study. Another
possible explanation is that the location from which the
patients and controls were recruited differed in the Tai-
wanese study. In the current study, we recruited both
patients and controls from the Aomori prefecture to
rule out any geography-related effects.
In this study, the trend relating OSI value and aging
among schizophrenic patients does not differ from that
in the general population in females. One possible
explanation is that the effects of menopause on bone
loss might exceed those of antipsychotic medication or
the disease itself. Estrogen deficiency at menopause
leads to increased skeletal remodeling and loss of bone
mass [22]. A decrease in estrogen levels can influence
the activity of interleukins, which are known to
Schizophrenic patients, maleGeneral population, male 
Schizophrenic patients, femaleGeneral population, female 
Age 
O
S
I
 
Figure 1 Scatterplots depicting the relationship between osteosono-assessment index (OSI) and age across subject populations and
genders. Lines indicate the slope of best fit with a 95% confidence interval by simple linear regression analysis.
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tive effect of estrogen to bone mass might explain the
earlier decline of bone mass among male schizophrenic
patients than female ones. Another possible explanation
is that secretion of estrogen or leptin from stored bodily
fat might protect bone loss in female patients with schi-
zophrenia, as these patients have more body fat [24,25]
than the general population. Previous studies [26,27]
have additionally shown a relationship between fat mass
and bone mineral density among females.
The mechanism for decreased bone mass among
patients with schizophrenia has not been entirely eluci-
dated. However, most antipsychotics block dopamine-
D2 receptors, attenuating the inhibitory effect of dopa-
mine on prolactin release from the pituitary gland and
resulting in hyperprolactinemia [28]. Previous studies
have shown that patients who are treated with antipsy-
chotics have elevated prolactin levels [6,29], which is
correlated with decreased bone mass in schizophrenic
patients. Even when a direct effect of prolactin on BMD
was not observed, the duration of antipsychotic treat-
ment had a tendency to be associated with decreased
BMD [30], and patients with hyperprolactinemia showed
higher rates of bone metabolism, including both bone
formation and resorption [5].
The present study has some limitations. First, mea-
surement of bone mass was based on QUS densitometry
instead of DXA scans. There are many researchers who
question the precision of peripheral bone mineral den-
sity measurements. Previous studies have reported that
QUS parameters cannot be used to predict decreased
BMD and that the sensitivities and specificities of QUS
parameters are not sufficient to allow it to be used as an
alternative to DXA [31-33], which is currently the gold
standard for measuring BMD [34,35]. However, most
psychiatric clinics do not have access to DXA equip-
ment and DXA scanning is time consuming, costly and
exposes patients to radiation, rendering it less than ideal
for a large population survey. In contrast, QUS is rapid
and portable, making it a suitable method for large stu-
dies. For these reasons, we chose to use this method for
our study. Second, because all participants of patients
and control consisted of volunteers, they may have
more interests in their health or be healthier than the
Table 2 Comparison of the prevalence of low bone mass in schizophrenic patients versus the general community in
Japanese subjects
Age subgroup, years Prevalence of low bone mass (t < 1.0) Prevalence of severe low bone mass (t < 2.5)
Schizophrenia, % Community, % Schizophrenia, % Community, %
Male:
20 to 29 0(0/20) 6.7 (1/15) 0(0/20) 0 (0/15)
30 to 39 27.9(12/43)* 7.1 (2/28) 0(0/43) 0 (0/28)
40 to 49 34.4(11/32)* 8.8 (5/57) 0(0/32) 0 (0/57)
50 to 59 42.5(17/40)* 12.2 (11/90) 2.5(1/40) 0 (0/90)
60 to 69 60(18/30)* 17.1 (13/76) 3.3(1/30) 0 (0/76)
70 or older 92.3(12/13)* 31.1 (19/61) 30.8(4/13)* 0 (0/61)
Female:
20 to 29 16.7(4/24) 13.3 (2/15) 0(0/24) 0 (0/15)
30 to 39 21.9(7/32) 15.0 (6/40) 0(0/32) 0 (0/40)
40 to 49 23.5(8/34) 24.2 (15/62) 0(0/34) 0 (0/62)
50 to 59 51.3(20/39) 54.4 (74/136) 2.6(1/39) 0 (0/136)
60 to 69 85.7(24/28) 78.0 (117/150) 7.1(2/28)* 0 (0/150)
70 or older 96.3(26/27) 85.3 (87/102) 14.8(4/27)* 1.0 (1/102)
The obtained data were analyzed using a c
2 test or Fisher’s exact test between schizophrenic patients and general community. *P < 0.05
Table 3 Comparison of osteosono-assessment index (OSI) by age and disease in each gender with general linear
model
Male Female
Coefficient SE P value Coefficient SE P value
Group (being schizophrenic) -0.318 0.149 P < 0.05 -0.091 0.104 P = 0.383
Age -0.015 0.002 P < 0.001 -0.019 0.001 P < 0.001
Group × age 0.011 0.003 P < 0.001 0.003 0.002 P = 0.079
Constant 3.459 0.110 P < 0.001 3.471 0.079 P < 0.001
To determine the factors associated with the measured OSI value, a general linear model that included subject groups (being schizophrenic), age, and interaction
(subject groups × age) was employed.
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all parameters which could affect bone mass were
included in this study such as body mass index, dietary
habits, smoking, alcohol intake, physical exercise, dura-
tion of illness and treatment, schizophrenic symptoms
and medications. Antipsychotic medications in particu-
lar may be an important factor, as the use of prolactin-
sparing or prolactin-raising antipsychotics might con-
found the results. Future research should endeavor to
consider the effects of drug treatment and lifestyle fac-
tors in conjunction with decreased bone mass in
schizophrenia.
Conclusions
This study has shown that the patients with schizophre-
nia have lower bone mass than the general population
in older age groups. However, the descending trend
between bone mass and aging among male schizophre-
nic patients is different from that observed in the male
community. This suggests that intervention programs to
either prevent or delay the onset of osteoporosis among
schizophrenic patients might be tailored separately for
each gender.
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